.png){kind=icon}
.png){kind=icon}
Return
Oral lactoferrin reduces systemic inflammation; enhances anti-viral responses and modulates immune cell profiles: a randomised controlled trial in healthy; older adults
.png){kind=icon}
OA
AI
B
E
L
K
S
N
L
DOI：10.1017/S000711452610631X.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
This randomised controlled trial examined the effect of a 4-week; high-dose (Lf-High; 600 mg/d) or low-dose (Lf-Low; 200 mg/d) oral lactoferrin (Lf) intervention v. placebo on immune cell responses to respiratory virus; immune cell subsets and systemic inflammation. In healthy older adults (n 103; ≥50 years old); ex vivo cytokine release of interferon (IFN)-α2; IFN-γ; IL-6 and TNF-α from rhinovirus A-16 (RV-16) or influenza A virus (H1N1) stimulated peripheral blood mononuclear cells; circulating immune cell subsets; and plasma IL-6; C-reactive protein (CRP) and TNF-α were assessed. Ninety-seven participants completed the 4-week intervention (Lf-High n 32; Lf-Low n 31; placebo n 34; withdrawals n 6). There was no difference in RV-16 or H1N1-induced IFN-γ release between groups. RV-16-induced IL-6 was lower in Lf-High v. placebo (P = 0·001); and RV-16-induced IFN-α2 was higher in Lf-High v. Lf-Low (P = 0·04). Lf-High increased total T cells (P = 0·03) and CD4+ T cells (P = 0·03) v. placebo. Lf-Low reduced neutrophil (P = 0·04); natural killer cell (P = 0·045); activated CD8+ T cell (P = 0·03) and γδ T cell (P = 0·03) frequency v. placebo. Plasma IL-6 (P = 0·004) and CRP (P = 0·03) were lower following Lf-High v. Lf-Low; but not placebo. Both high- and low-dose Lf altered ex vivo immune cell responses after 4 weeks. High-dose increased T-cell subsets; promoting adaptive immunity; and reduced systemic inflammation; while low-dose reduced proinflammatory and cytotoxic immune cells. High- and low-dose Lf supplements may have immunoceutical benefits in older adults.
Keywords:
Lactoferrin
immune function
systemic inflammation
randomised controlled trial
blood dendritic cell antigen
C-reactive protein
dendritic cell
interferon
lactoferrin
natural killer
blood mononuclear cell
rhinovirus A-16
toll-like receptor
Journal
IF:
3
Papers:
1.0W
Citations:
2.8W
Organization
Cited Papers